HPV status and HPV16 viral load in anal cancer and its association with clinical outcome

Daniel Guerendiain, Raluca Grigorescu, Anna Kirk, Andrew Stevenson, Matthew T. G. Holden, Jiafeng Pan, Kim Kavanagh, Sheila V. Graham, Kate Cuschieri

Research output: Contribution to journalArticlepeer-review

6 Citations (Scopus)
25 Downloads (Pure)


The incidence of anal cancer is increasing globally. Evidence-based improvement in early detection and management of this morbid cancer is thus required. In other cancers associated with Human Papillomavirus (HPV), viral status and dynamics, including viral load (VL) has been shown to influence clinical outcome. Our aim was to determine the influence of HPV status and HPV16 VL on the clinical outcomes of anal cancer patients. A total of 185 anal cancer lesions were genotyped for HPV. Of the HPV16 positive component, VL was determined using a digital droplet PCR assay. The association of qualitative HPV status and VL (low (57 copies/cell)) on overall survival and hazard of death was assessed. Of the 185 cases, 164 (88.6%) samples were HPV positive. HPV16 was detected in 154/185 samples (83.2%). HPV positive status was associated with improved overall survival in the univariate analysis [hazard ratio (HR) of 0.44, 0.23-0.82, p = 0.01]. When adjusted by age, sex, stage and response to treatment, the association of positive HPV status with improved survival remained (HR 0.24 [0.11-0.55] p 
Original languageEnglish
Pages (from-to)4193-4203
Number of pages11
JournalCancer Medicine
Issue number22
Early online date4 Jul 2022
Publication statusPublished - Nov 2022


  • viral load
  • clinical outcome
  • anal cancer


Dive into the research topics of 'HPV status and HPV16 viral load in anal cancer and its association with clinical outcome'. Together they form a unique fingerprint.

Cite this